Use of sting agonists to treat chronic hepatitis b virus infection
AssigneeDrexel University
InventorsJINHONG CHANG, FANG GUO, TIMOTHY M. BLOCK, JU-TAO GUO
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating a subject having hepatitis B viral (HBV) infection. More specifically, disclosed herein are methods of stimulating the innate cytokine response in macrophages, dendritic cells and/or liver non-parenchymal cells with small molecular agonists of STING to suppress HBV replication in hepatocytes. The methods are especially suitable for use in the treatment of chronic HBV infections. Also disclosed herein are methods of identifying compounds useful in the treatment of HBV infection.
Claims24
A method of treating a subject having a hepatitis B viral infection, the method comprising administering an effective amount of a STING agonist to said subject.
A method of identifying compounds useful in the treatment of hepatitis B virus infection, the method comprising:
- treating liver resident dendritic cells, macrophages, nonparenchymal cells, or any combination thereof with a compound of interest;
- incubating the treated cells in a conditioned medium;
- removing the conditioned medium or a portion thereof from the treated cells;
- and
- incubating hepatitis B virus infected hepatocytes with the conditioned medium.
A method of treating a subject having a hepatitis B virus infection, the method comprising:
- treating liver resident dendritic cells, macrophages, nonparenchymal cells, or any combination thereof, with a compound of interest;
- incubating the treated cells in a conditioned medium;
- removing the conditioned medium or a portion thereof from the treated cells;
- and
- administering the conditioned medium or a portion thereof to said subject.
Dependencies are inferred from the claim text.